Incretin Atlas › Molecules › Cotadutide
Cotadutide
GLP-1/GCG · s.c. · AstraZeneca
Summary
- Also known as
- MEDI0382, AstraZeneca
- Mechanism
- GLP-1/GCG
- Route
- s.c.
- Company
- AstraZeneca
- Highest development stage
- phase 2
- Status (as of data cut)
- Phase 2 (MASH, CKD with T2D) completed; no phase 3 registered verify
- Next milestone
- —
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 0 no data | ||
| T2D | 0 no data | ||
| CV outcomes | 0 no data | ||
| CKD | 1 phase 2 / signal | Phase 2 in CKD with T2D | Cotadutide phase 2 CKD |
| HFpEF | 0 no data | ||
| MASH | 1 phase 2 / signal | Phase 2 in NASH with fibrosis | Cotadutide phase 2 NASH |
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
No trial arms with extracted efficacy or tolerability data yet.
Registered trials (3)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| PROXYMO-ADV A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis | MASH | Phase 2 | completed | 2022-07 → 2024-04 | 54 | Completed; results not in the atlas yet | NCT05364931 |
| NCT04515849 A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus | CKD | Phase 2 | completed | 2020-08 → 2022-03 | 248 | Completed; results not in the atlas yet | NCT04515849 |
| NCT04019561 A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. | MASH | Phase 2 | completed | 2019-09 → 2021-05 | 74 | Completed; results not in the atlas yet | NCT04019561 |
Primary sources
No source recorded.
How to cite this page
Medical Adviser's Group. Incretin Atlas: Cotadutide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/cotadutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.